Chris Schott
Stock Analyst at JP Morgan
(3.50)
# 870
Out of 4,876 analysts
130
Total ratings
56.98%
Success rate
2.13%
Average return
Main Sectors:
Stocks Rated by Chris Schott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $950 → $800 | $521.00 | +53.55% | 7 | Jun 9, 2025 | |
| TEVA Teva Pharmaceutical Industries | Upgrades: Overweight | $21 → $23 | $16.76 | +37.23% | 16 | May 12, 2025 | |
| BIIB Biogen | Maintains: Neutral | $185 → $175 | $126.08 | +38.80% | 4 | May 5, 2025 | |
| GILD Gilead Sciences | Maintains: Overweight | $120 → $130 | $110.67 | +17.47% | 6 | Mar 27, 2025 | |
| AMRX Amneal Pharmaceuticals | Upgrades: Overweight | $9 → $12 | $8.13 | +47.60% | 2 | Feb 24, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $210 → $200 | $182.31 | +9.70% | 2 | Nov 13, 2024 | |
| IDXX IDEXX Laboratories | Maintains: Overweight | $630 → $575 | $531.32 | +8.22% | 7 | Oct 11, 2024 | |
| ZTS Zoetis | Maintains: Overweight | $225 → $230 | $156.17 | +47.28% | 2 | Oct 11, 2024 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $1,050 → $1,100 | $775.45 | +41.85% | 20 | Sep 13, 2024 | |
| OGN Organon & Co. | Downgrades: Underweight | $18 → $20 | $9.86 | +102.84% | 2 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $41 | $26.54 | +54.48% | 11 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $42 | $35.87 | +17.09% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $270 | $277.13 | -2.57% | 1 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $34 | $24.19 | +40.55% | 10 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $125 | $79.10 | +58.03% | 7 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $14 | $9.01 | +55.38% | 2 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $11 | $0.74 | +1,380.29% | 4 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $20 | $14.29 | +39.96% | 3 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $6.46 | - | 4 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $78 | $46.35 | +68.28% | 7 | Oct 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $700 → $950 | $4.62 | +20,462.77% | 4 | May 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.15 | - | 2 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $45 → $50 | $23.48 | +112.95% | 3 | Nov 2, 2018 |
Regeneron Pharmaceuticals
Jun 9, 2025
Maintains: Overweight
Price Target: $950 → $800
Current: $521.00
Upside: +53.55%
Teva Pharmaceutical Industries
May 12, 2025
Upgrades: Overweight
Price Target: $21 → $23
Current: $16.76
Upside: +37.23%
Biogen
May 5, 2025
Maintains: Neutral
Price Target: $185 → $175
Current: $126.08
Upside: +38.80%
Gilead Sciences
Mar 27, 2025
Maintains: Overweight
Price Target: $120 → $130
Current: $110.67
Upside: +17.47%
Amneal Pharmaceuticals
Feb 24, 2025
Upgrades: Overweight
Price Target: $9 → $12
Current: $8.13
Upside: +47.60%
AbbVie
Nov 13, 2024
Maintains: Overweight
Price Target: $210 → $200
Current: $182.31
Upside: +9.70%
IDEXX Laboratories
Oct 11, 2024
Maintains: Overweight
Price Target: $630 → $575
Current: $531.32
Upside: +8.22%
Zoetis
Oct 11, 2024
Maintains: Overweight
Price Target: $225 → $230
Current: $156.17
Upside: +47.28%
Eli Lilly and Company
Sep 13, 2024
Maintains: Overweight
Price Target: $1,050 → $1,100
Current: $775.45
Upside: +41.85%
Organon & Co.
Sep 6, 2024
Downgrades: Underweight
Price Target: $18 → $20
Current: $9.86
Upside: +102.84%
Feb 28, 2024
Maintains: Overweight
Price Target: $48 → $41
Current: $26.54
Upside: +54.48%
Feb 20, 2024
Maintains: Overweight
Price Target: $45 → $42
Current: $35.87
Upside: +17.09%
Oct 20, 2023
Reinstates: Neutral
Price Target: $270
Current: $277.13
Upside: -2.57%
Oct 16, 2023
Maintains: Neutral
Price Target: $36 → $34
Current: $24.19
Upside: +40.55%
Feb 23, 2023
Maintains: Overweight
Price Target: $120 → $125
Current: $79.10
Upside: +58.03%
Nov 15, 2022
Maintains: Neutral
Price Target: $13 → $14
Current: $9.01
Upside: +55.38%
Nov 14, 2022
Maintains: Neutral
Price Target: $13 → $11
Current: $0.74
Upside: +1,380.29%
Oct 17, 2022
Maintains: Neutral
Price Target: $24 → $20
Current: $14.29
Upside: +39.96%
Jul 29, 2022
Downgrades: Neutral
Price Target: n/a
Current: $6.46
Upside: -
Oct 16, 2020
Maintains: Overweight
Price Target: $74 → $78
Current: $46.35
Upside: +68.28%
May 27, 2020
Maintains: Overweight
Price Target: $700 → $950
Current: $4.62
Upside: +20,462.77%
May 19, 2020
Downgrades: Neutral
Price Target: n/a
Current: $1.15
Upside: -
Nov 2, 2018
Maintains: Neutral
Price Target: $45 → $50
Current: $23.48
Upside: +112.95%